Date Log
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Evaluating the Neonatal Formulation of Famotidine in a Live Setting
Corresponding Author(s) : Golla Anjali Yadav
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 12 No. 4 (2024): 2024 Volume -12 - Issue 4
Abstract
Oral controlled release (CR) dosage forms (DFs) have been developed over the past three decades due to their considerable therapeutic advantages such as ease of administration, patient compliance and flexibility in formulation. However, this approach is bedilled with several physiological difficulties such as inability to restrain and locate the controlled drug delivery system within the desired region of the gastrointestinal tract (GIT) due to variable gastric emptying and motility. Furthermore, the relatively brief gastric emptying time (GET) in humans which normally averages 2-3 through the major absorption zone, i.e., stomach and upper part of the intestine can result in incomplete drug release from the drug delivery system leading to reduced efficacy of the administered dose. Therefore, control of placement of a drug delivery system (DDS) in a specific region of the GI tract offers advantages for a variety of important drugs characterized by a narrow absorption window in the GIT or drugs with a stability problem.These considerations have led to the development of a unique oral controlled release dosage form with gastro retentive properties. After oral administration, such a DF would be retained in the stomach and release the drug there in a controlled and prolonged manner, the drug could be supplied continuously to its absorptions in the upper gastrointestinal tract. Gastro retentive dosage form can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs. Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility of drugs that are less soluble in a high pH environment. It is also suitable for local drug delivery to the stomach and proximal small intestine.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. IntJPharm.1996;136:117-139.
- Singh BN and Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release. 2000; 63: 235-239.
- StreubelA, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin DrugDeliv.2006;3(2):217-233.
- Ali J, Arora S, Khar RK. Floating drug delivery System: A Review. AAPS PharmSciTech.2005; 06(03): E372-E390.
- Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of an over controlled-release system for gastric retention. PharmRes.1997; 14:815-819.
- Davis SS, Stockwell AF, Taylor MJ. The effect of density on the gastric emptying of single and multiple unit dosage forms. PharmRes.1986;3:208-213.
- LehrCM. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit.Rev.Ther.DrugCarrierSyst.1994;11:119-160.
- Groning R, Heun G. Oraldosage forms with controlled gastrointestinal transit. DrugDev IndPharm.1984;10:527-539.
- Groning R, Heun G. Dosage forms with controlled gastrointestinal passage studies on the absorption of nitrofurantion. IntJPharm.1989;56:111-116.
- Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003; 90: 143 162.
- Vaishali sharma, Lalit Singh, Vijay Sharma, A novel approach to combat regional variability:floating drug delivery system, Volume 8, Issue 2, May – June 2011;Article-026
- Dave B.S, Amin A.F and Patel M.M, Gastroretentive drug delivery system of Ranitidine hydrochloride formulation and invitro evaluation, AAPS Pharm. SciTech(2004),5(2),1-6.
- Amit kumarnayak*, Ruma Maji, Biswarup Das, Gastroretentive drug delivery systems are view, vol.3, issue1,jan-march 2010
- S.S. Davis, 2005, Drug DiscoveryToday:Vol.10249-256.
- Fix, J.A; Cargil, R; Engle, K; Gastric residence time of an on-disintegrating geometric shape in human volunteers, Pharm.Res.1995, 12(3),397-405.
- Desai,S; A floating controlled release drug delivery system; invitro/invivo evaluation, pharm.Res, 1993,10,1321-1325.
- GuptaP.,VermaniK.,andGrgS.,hydrogels:fromcontrolledreleasetoPHresponsivedrugdelivery, drug discovery today 7(10),2002,569-579.
- BabuVBM, KharRk, Invitro and invivo studies of sustained release floating dosage forms containing salbutamol sulphate,pharmazie,1990;45:268-270
- HetalNKikani, AThesison Floating Drug Delivery System, The North Gujarat University, Patan, 2000-2001; 11-12.
- R Garg*, GD Gupta, Progress in controlled gastroprotective delivery systems, Tropical Journal of Pharmaceutical Research, September 2008;7(3):1055-1066.
References
Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site specific delivery. IntJPharm.1996;136:117-139.
Singh BN and Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J. Control. Release. 2000; 63: 235-239.
StreubelA, Siepmann J, Bodmeier R. Gastroretentive drug delivery system. Expert Opin DrugDeliv.2006;3(2):217-233.
Ali J, Arora S, Khar RK. Floating drug delivery System: A Review. AAPS PharmSciTech.2005; 06(03): E372-E390.
Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of an over controlled-release system for gastric retention. PharmRes.1997; 14:815-819.
Davis SS, Stockwell AF, Taylor MJ. The effect of density on the gastric emptying of single and multiple unit dosage forms. PharmRes.1986;3:208-213.
LehrCM. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit.Rev.Ther.DrugCarrierSyst.1994;11:119-160.
Groning R, Heun G. Oraldosage forms with controlled gastrointestinal transit. DrugDev IndPharm.1984;10:527-539.
Groning R, Heun G. Dosage forms with controlled gastrointestinal passage studies on the absorption of nitrofurantion. IntJPharm.1989;56:111-116.
Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003; 90: 143 162.
Vaishali sharma, Lalit Singh, Vijay Sharma, A novel approach to combat regional variability:floating drug delivery system, Volume 8, Issue 2, May – June 2011;Article-026
Dave B.S, Amin A.F and Patel M.M, Gastroretentive drug delivery system of Ranitidine hydrochloride formulation and invitro evaluation, AAPS Pharm. SciTech(2004),5(2),1-6.
Amit kumarnayak*, Ruma Maji, Biswarup Das, Gastroretentive drug delivery systems are view, vol.3, issue1,jan-march 2010
S.S. Davis, 2005, Drug DiscoveryToday:Vol.10249-256.
Fix, J.A; Cargil, R; Engle, K; Gastric residence time of an on-disintegrating geometric shape in human volunteers, Pharm.Res.1995, 12(3),397-405.
Desai,S; A floating controlled release drug delivery system; invitro/invivo evaluation, pharm.Res, 1993,10,1321-1325.
GuptaP.,VermaniK.,andGrgS.,hydrogels:fromcontrolledreleasetoPHresponsivedrugdelivery, drug discovery today 7(10),2002,569-579.
BabuVBM, KharRk, Invitro and invivo studies of sustained release floating dosage forms containing salbutamol sulphate,pharmazie,1990;45:268-270
HetalNKikani, AThesison Floating Drug Delivery System, The North Gujarat University, Patan, 2000-2001; 11-12.
R Garg*, GD Gupta, Progress in controlled gastroprotective delivery systems, Tropical Journal of Pharmaceutical Research, September 2008;7(3):1055-1066.